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Prognostic value of routine 
laboratory variables in prediction of 
breast cancer recurrence
Zhu Zhu1,2, Ling Li2, Zhong Ye2, Tong Fu1, Ye Du1, Aiping Shi1, Di Wu1, Ke Li3, Yifan Zhu2,  
Chun Wang2,4 & Zhimin Fan1
The prognostic value of routine laboratory variables in breast cancer has been largely overlooked. 
Based on laboratory tests commonly performed in clinical practice, we aimed to develop a new model 
to predict disease free survival (DFS) after surgical removal of primary breast cancer. In a cohort of 1,596 
breast cancer patients, we analyzed the associations of 33 laboratory variables with patient DFS. Based 
on 3 significant laboratory variables (hemoglobin, alkaline phosphatase, and international normalized 
ratio), together with important demographic and clinical variables, we developed a prognostic model, 
achieving the area under the curve of 0.79. We categorized patients into 3 risk groups according to the 
prognostic index developed from the final model. Compared with the patients in the low-risk group, 
those in the medium- and high-risk group had a significantly increased risk of recurrence with a hazard 
ratio (HR) of 1.75 (95% confidence interval [CI] 1.30–2.38) and 4.66 (95% CI 3.54–6.14), respectively. 
The results from the training set were validated in the testing set. Overall, our prognostic model 
incorporating readily available routine laboratory tests is powerful in identifying breast cancer patients 
who are at high risk of recurrence. Further study is warranted to validate its clinical application.
Breast cancer is currently the most frequently diagnosed cancer and the leading cause of cancer-related mortal-
ity in women. Excluding skin cancers, breast cancer accounts for nearly 1 in 3 cancers1. In 2015, an estimated 
231,840 new cases of invasive breast cancer will be diagnosed among women in the U.S., and approximately 
40,290 women are expected to die from breast cancer2. Overall breast cancer death rates decreased 36% from 1989 
to 2012 due to improvements in early detection and systemic therapies2–4. However, recurrence is still a major 
concern after surgical removal of primary breast tumor. Most locoregional failures occur within 5 years5. Both 
ipsilateral breast tumor recurrence and other locoregional recurrences are associated with significantly increased 
risk of distant disease and death5, 6.
A number of clinical and biological prognostic factors, such as age, performance status, sites of disease, hor-
mone receptor status, and therapies, are associated with long-term clinical outcomes among women with breast 
cancer7. At present, the prognosis, classification, and treatment of breast cancer are dependent on tumor histolog-
ical grade, lymph node stage, tumor stage, as well as 3 major protein markers: estrogen receptor (ER), progester-
one receptor (PR), and human epidermal growth factor receptor 2 (HER2)4, 8. Several recent studies incorporated 
various genetic and molecular biomarkers to develop new prognostic models for breast cancer9. Nevertheless, 
most of the markers are not yet available in routine clinical practice, and their applicability may be limited by high 
cost and the need for specialized equipment and expertise. Therefore, development of novel prognostic models 
based on easily available markers from routine clinical practice, will benefit oncologists in identifying patients at 
risk of locoregional recurrences and distant metastases so as to utilize more efficient patient-tailored treatment 
strategies.
In this study we hypothesized that a model incorporating biomarkers from conventional laboratory tests may 
provide valuable information on breast cancer prognosis. To test this hypothesis, we analyzed the associations 
between 33 routine blood-based laboratory tests and disease free survival (DFS) of patients with breast cancer. 
Incorporating variables which were significantly associated with DFS in univariate analysis into our prognostic 
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model could better stratify patients into different risk groups. Thus, we offer a new prognostic model which is a 
noninvasive and inexpensive tool to aid physicians in estimating patient survival.
Results
Characteristics of study population. A total of 1,596 histologically confirmed breast cancer patients were 
included in this study. The detailed selection criteria are depicted in Fig. 1. Among the 1,596 patients, 1,053 
(66.0%) patients were recurrence-free during follow-up, and 543 (34.0%) patients had recurrent disease or died. 
The patients were divided into a training set (N = 1,064) and a testing set (N = 532). The median follow-up time 
was 3.6 years (interquartile range [IQR] 1.8–8.2) and 4.2 years (IQR 2.0–8.3) in the training and testing set, 
respectively (P = 0.30). Demographic and basic clinical variables are summarized in Table 1. The differences 
between the training and testing sets were not statistically significant for almost all the demographic and clinical 
variables, except for tumor grade with a borderline significance (P = 0.04). The mean values of 33 laboratory 
variables are listed in Supplementary Table S1. A total of 12 variables with more than 50% missing observations 
were excluded from further analysis. The missing values of the remaining 21 variables ranged from 3.0% to 45.8% 
in the training set.
Univariate analysis. Kaplan-Meier and univariate Cox proportional hazards regression analysis were used 
to select candidate variables to be included in stepwise selection. Ten demographic and basic clinical variables 
(age, race, tumor stage, tumor size, lymph nodes metastatic rate, ER status, PR status, chemotherapy, radiation 
therapy, and hormone therapy) were significantly associated with DFS (Supplementary Table S2). Among the 
remaining 21 laboratory variables, 8 exhibited significant associations with DFS in a univariate basis (Table 2), 
including HCT, HGB, RBC, and RDW from the CBC panel, albumin and ALP from the CMP panel, and INR and 
PT from the coagulation panel. All of these 8 variables were significant when they were analyzed as both categor-
ical and continuous variables, as well as in log-rank analysis. They were included as candidate prognostic factors 
in the next step of stepwise selection and model construction.
Stepwise selection and final model construction. Multiple imputation method was used to generate 
10 imputed datasets from the training set, and stepwise selection was conducted forward to identify the best 
group of variables to be included in the multivariate Cox proportional hazards model for each imputed dataset. 
The number of times that each of the 8 variables was selected for inclusion in the model by stepwise selection 
is summarized in Supplementary Table S3. Three variables (HGB, ALP, and INR) which were selected from ≥6 
imputed datasets were included in the final model. The parameter estimates (regression coefficients or weights) 
and standard errors of the 10 significant demographic and basic clinical variables (age, race, stage, tumor size, 
lymph nodes metastatic rate, ER status, PR status, chemotherapy, radiation therapy, and hormone therapy), as 
well as, 3 laboratory variables (HGB, ALP, and INR) in the final model are showed in Table 3. As showed in 
Supplementary Table S4, the prognostic index was calculated for each patient based on the final model.
Model validation. The prognostic utility of the final model was measured by the area under the curve (AUC) 
of receiver operating characteristics (ROC) curve. The AUCs were 0.79 (95% CI: 0.75–0.83) and 0.74 (95% CI: 
0.69–0.79) in the training and testing set, respectively (Fig. 2). We repeated the analyses after exclusion of the 
Figure 1. Diagram of Study Population Selection. All of patients were histologically confirmed as having breast 
cancer and were diagnosed and/or treated in the Kimmel Cancer Center at the Thomas Jefferson University 
Hospital. A cohort of 1,596 breast cancer patients was included in this study based on the selection criteria.
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Patients characteristic Training set N = 1,064 (%) Testing set N = 532 (%) P value
Age, mean ± SD, (years) 59.0 ± 14.0 59.6 ± 12.9 0.35
Race/ethnicity 0.91
 Caucasian 777 (73.0) 390 (73.3)
 African American 214 (20.1) 112 (21.0)
 Asian 42 (4.0) 17 (3.2)
 Others 12 (1.1) 5 (0.9)
 Unknown 19 (1.8) 8 (1.5)
Smoking status 0.55
 Never smoking 571 (53.7) 265 (49.8)
 Current smoking 124 (11.6) 67 (12.6)
 Former smoking 215 (20.2) 116 (21.8)
 Unknown 154 (14.5) 84 (15.8)
Drinking status 0.99
 Never drinking 482 (45.3) 237 (44.5)
 Current drinking 380 (35.7) 192 (36.1)
 Former drinking 6 (0.6) 3 (0.6)
 Unknown 196 (18.4) 100 (18.8)
Tumor stage 0.73
 Stage I 566 (53.2) 275 (51.7)
 Stage II 355 (33.4) 190 (35.7)
 Stage III 112 (10.5) 53 (10.0)
 Stage IV 31 (2.9) 14 (2.6)
Tumor grade 0.04
 Well differentiated 121 (11.4) 87 (16.4)
 Moderately differentiated 410 (38.5) 201 (37.8)
 Poorly differentiated 395 (37.1) 178 (33.5)
 Not determined 138 (13.0) 66 (12.4)
Tumor histology 0.80
 Invasive ductal carcinoma 868 (81.6) 438 (82.3)
 Invasive lobular carcinoma 74 (6.9) 38 (7.1)
 Mixed carcinoma 106 (10.0) 46 (8.7)
 Othersa 16 (1.5) 10 (1.9)
Tumor size 0.47
 2–9 mm 181 (17.0) 98 (18.4)
 10–29 mm 447 (42.0) 232 (43.6)
 30–49 mm 106 (10.0) 54 (10.1)
 50–99 mm 71 (6.7) 28 (5.3)
 ≥10 cm 13 (1.2) 2 (0.4)
 Unknown/not found 246 (23.1) 118 (22.2)
Lymph nodes metastatic 
rate 0.50
 0% 591 (55.5) 289 (54.3)
 1–20% 128 (12.0) 77 (14.5)
 20–49% 55 (5.2) 31 (5.8)
 50–79% 32 (3.0) 23 (4.3)
 80–100% 34 (3.2) 15 (2.8)
 Not determined 176 (16.5) 76 (14.3)
 Unknown 48 (4.5) 21 (4.0)
Estrogen receptor status 0.77
 Negative 223 (21.0) 104 (19.6)
 Positive 734 (69.0) 371 (69.7)
 Unknown 107 (10.0) 57 (10.7)
Progesterone receptor status 0.76
 Negative 313 (29.5) 154 (28.9)
 Positive 642 (60.3) 317 (59.6)
 Unknown 109 (10.2) 61 (11.5)
Chemotherapy 0.97
Continued
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patients who were followed less than 3, 6, or 12 months. Increasing the length of the exclusion window min-
imizes potential confounding effects at the time of baseline sample collections. In the subset of patients who 
were followed ≥3 months, the AUCs in the training and testing sets were the same as that in the overall patients 
(Supplementary Figure S1A). Very similar results were observed in the subsets of patients who were followed 
either ≥6 or ≥12 months (Supplementary Figure S1B and C).
The patients were then classified into three risk groups according to the tertile distribution of the prognostic 
index. Compared with patients in the low-risk group, patients in the medium- and high-risk group had a signifi-
cantly increased risk of recurrence with a hazard ratio (HR) of 1.75 (95% confidence interval [CI] 1.30–2.38) and 
4.66 (95% CI 3.54–6.14), respectively in the training set (Table 4). The survivals were significantly different among 
these three risk groups (P < 0.0001, Fig. 3A). Similar results were found in the testing set (Table 4 and Fig. 3B), as 
well as, in the subset analyses (Supplementary Figure S2).
Discussion
In this study, we assessed the associations of a large panel of 33 laboratory variables available in routine clinical 
practice, with the DFS of a cohort of patients with breast cancer. Three laboratory variables were demonstrated 
to be associated with DFS and were used to construct a prognostic model that could be used to identify patients 
at risk of recurrence.
There is not widely accepted prognostic model based on objective criteria other than predicting survival using 
clinical features. In addition to demographic and basic clinical information, an increasing number of novel prog-
nostic markers have been explored and identified10–12. However, the main problem for most of these studies 
is that biomarkers rely on sophisticated molecular and/or genetic tests11, 13–16. The practical application of the 
novel tests is inevitably restricted by its cost and complexity. Comparatively, the prognostic model developed 
in this study uses laboratory test results which have already been available as a consequence of routine clinical 
monitoring, at no incremental cost. Combining demographic and basic clinical information, together with these 
laboratory parameters, we developed a new prognostic model that may help physicians and patients estimate DFS 
and thereby inform medical decision-making and patient counseling.
Accumulating evidence has shown that black women have a high risk of breast cancer recurrence regardless 
of age and tumor size17, 18. We previously reported a racial disparity in breast cancer survival using the Jefferson 
Cancer Registry data19. In the current study, the risk of recurrence increased by 54% in African Americans com-
pared to Caucasians, again demonstrating the prognostic value of race. Therefore, the inclusion of race, as well 
as other well-known predictors such as age, tumor characteristics, and treatments20 in the model makes the final 
model reliable in recurrence prediction and applicable in clinics. Our previous study also found that differences 
in tumor presentation and certain hematologic traits, for example HGB level were associated with racial disparity 
in breast cancer survival19. Abnormal metabolic index at baseline were reported to affect survival for all stages of 
breast cancer as well21. In the present study, three laboratory variables (HGB, ALP, and INR) which were signif-
icantly associated with patient DFS in univariate analyses were stepwise selected into the final model to predict 
patient survival. There are plausible physiological reasons why each of these variables might be an important 
predictor.
It is not uncommon for a cancer patient to have anemia. Besides radiotherapy and chemotherapy, cancer 
itself could cause anemia of chronic disease. The mechanism of anemia may be because of decreased lifetime of 
RBC, decreased sensitivity of bone marrow to erythropoietin, and decreased production of erythropoietin22. Not 
mentioning neoplasm itself has a higher need for nutrition, and some cytokines secreted by neoplasm cells could 
depress one’s appetite23, which may take parts in the development of cachexia, and devastating prognosis there-
after. A proportion of 62% to 71% breast cancer patients would have anemia during their courses of disease24, 25. 
The scale of anemia may accord to the phase of breast cancer and the medication of chemotherapy26, 27. Anemia, 
or HGB level, has been found to have strong relationship with recurrence and prognosis of breast cancer by the 
studies of ours and others28–34.
Bone is a common site of metastatic breast cancer. Skeletal isoenzyme of ALP increases when there is 
bone reconstruction. The mRNA of ALP expression elevates in cancer cells, and may participate in mammary 
Patients characteristic Training set N = 1,064 (%) Testing set N = 532 (%) P value
 No 618 (58.1) 307 (57.7)
 Yes 414 (38.9) 208 (39.1)
 Unknown 32 (3.0) 17 (3.2)
Radiation therapy 0.12
 No 603 (56.7) 290 (54.5)
 Yes 427 (40.1) 214 (40.2)
 Unknown 34 (3.2) 28 (5.3)
Hormone therapy 0.64
 No 652 (61.3) 323 (60.7)
 Yes 339 (31.9) 178 (33.5)
 Unknown 73 (6.9) 31 (5.8)
Table 1. Characteristics of patients in the training and testing sets. Abbreviations: SD, standard deviation. 
aOthers include colloid, medullary, tubular, papillary carcinoma, and Paget’s disease.
www.nature.com/scientificreports/
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mineralization just like ossification formed by osteoblast cells35. ALP is also a sensitive indicator of biliary block-
age, and it is more reliable than other liver enzymes when there is a liver metastasis involved36. Therefore, it 
is reasonable that ALP, as a valuable prognostic marker, was selected in our final prognostic model. However, 
a recent study by Liu et al. failed to identify the association of pretreatment ALP level with overall survival in 
female Caucasian patients with non-metastatic invasive breast cancer37. It was reported previously that ALP may 
not increase much in early stage breast cancer patients, but there would be a significant increase in patients with 
metastatic disease38. Thus, the different findings between ours and Liu’s study may be due to the differences in 
patient characteristics (age, gender, and ethnicity) and cancer biology (cancer stage, histological types, and so on).
Tissue factor is a major participant of abnormal coagulation in cancer patients. The expression of tissue factor 
increases in many different neoplasm models, and has very strong relationship with severity and prognosis39, 
40. Several studies have established connection between tissue factor and neoplasm growth and invasion41–43. 
Although breast cancer cells were reported to produce lower level of tissue factor compared to other cancer cell 
types44, high level of tissue factor was observed in studies focus more on chemotherapy of breast cancer patients 
when thrombosis was involved45–47. Tissue factor is not measured routinely, but factor VII function is often meas-
ured through PT or INR48, 49. So it may not be surprising that our final model including INR could be used to 
predict patient recurrence.
Several clinical tools have been developed to predict prognosis and survival benefit from treatments, using 
clinicopathological features, genetic profiles, and novel biomarkers50. In 466 invasive ductal carcinoma breast can-
cer patients, Volinia and Croce reported an AUC of 0.74 by integrating mRNA, microRNA, and DNA methylation 
next-generation sequencing data into the model51. Based on large database of microarray datasets, Griffith et al. 
developed a robust multi-gene mRNA transcription-based predictor of relapse free survival at 10 years, which 
achieved an AUC of 0.70 for hormone-positive node-negative breast cancer patients52. Using clinicopathologi-
cal features and all 14 biomolecular signatures, Campbell et al. reported an AUC of 0.75 in early breast cancer 
patients, aiming to predict relapse-free survival53. Inevitably, molecular markers included in these studies added 
additional costs and limited clinical generalization. And apparently, those derived biomarkers which are not 
clinically certified, may exhibit large variations when measured in different laboratories. In comparison, the lab-
oratory variables we used are inexpensive, readily available, and technically simple. Another prognostic index, 
the Nottingham Prognostic Index (NPI) is also widely used for predicting survival of operable primary breast 
cancer54, 55. NPI based on tumor size, histologic grade, and lymph node status56, although is simple and easily 
available in routine clinics, provided suboptimal performance in predicting patient recurrence57–60. The AUCs for 
NPI in our study were 0.66 and 0.63 in the training and testing sets, respectively (data not shown). Our current 
model including demographic and basic clinical variables, as well as 3 routine laboratory variables exhibited a 
Variablesa % of missing value
No. of patients disease 
free/recurrence HR (95% CI) Cox P Log-rank P Brootstrap % (<0.05)
HCT 3.57 <0.0001 98.1
  ≤37.48% 295/218 1.00
  >37.48% 358/155 0.65 (0.53–0.80) <0.0001
HGB 3.48 <0.0001 99.7
  ≤12.50 T/L 306/211 1.00
  >12.50 T/L 348/162 0.62 (0.51–0.76) <0.0001
RBC 3.01 <0.0001 97.9
  ≤4.19 T/L 300/216 1.00
  >4.19 T/L 358/158 0.67 (0.54–0.82) 0.0001
RDW 3.57 <0.0001 100.0
  ≤13.40% 371/160 1.00
  >13.40% 282/213 1.85 (1.51–2.27) <0.0001
Albumin 36.09 0.03 70.1
  ≤4.30 g/dL 266/115 1.00
  >4.30 g/dL 191/108 0.74 (0.57–0.97) 0.03
ALP 30.64 0.002 87.4
  ≤69 IU/L 268/111 1.00
  >69 IU/L 224/135 1.48 (1.15–1.91) 0.002
INR 39.85 <0.0001 99.9
  ≤1.02 234/99 1.00
  >1.02 175/132 2.00 (1.54–2.60) <0.0001
PT 45.77 <0.0001 100.0
  ≤13.55 214/75 1.00
  >13.55 147/141 2.14 (1.61–2.85) <0.0001
Table 2. Candidate laboratory variables selected by univariate analysis in the training set. Abbreviations: 
RBC, red blood cell; HGB, hemoglobin; HCT, hematocrit; RDW, red cell distribution width; INR, international 
normalized ratio; ALP, alkaline phosphatase; HR, hazard ratio; CI, confidence interval. aVariables were 
categorized by the median value in the study population.
www.nature.com/scientificreports/
6SciEnTiFic RePoRtS | 7: 8135  | DOI:10.1038/s41598-017-08240-2
prognostic power superior to previously reported models either using routine clinical variables, or using more 
expensive and complicated molecular biomarkers.
There are several strengths of our study. We had a relatively large population with 1,596 breast cancer patients 
and the final results were consistent between training and testing sets. We analyzed DFS of breast cancer patients 
after surgery to enhance the application of our model, given patients are at high risk of recurrence during the first 
5 years of treatments. Generally, the measurements of laboratory variables around time of diagnosis are more rel-
evant to a prediction model, however, are affected by factors such as treatments. Therefore, we restricted the anal-
yses on laboratory variables measured within 3 months after surgery to minimize the influence of certain causes 
on the variables, such as less reliable test results due to longer time after surgery, or inaccurate test results due 
to adverse effects after treatments applied. Furthermore, compared to published survival models based on more 
specialized and expensive biomarkers identified by gene/protein expression assays, our current model relying on 
easily obtained hematological index from routine clinical practice exhibits a comparative prognostic performance 
but without increased cost. There are several limitations of this study. First, although our findings are internally 
validated and the selected variables in the final model are physiologically plausible, our cohort was from a single 
institution. The results from our current study should be further validated in large independent populations. 
Second, we collected the hematological indexes detected within 3 months after surgery and related records avail-
able in our medical charts. Some indexes which were examined during follow-ups at a long or irregular interval 
exhibited high percentages of missing values, possibly because they may only be requested to be tested when a 
clinical sign or side effect was detected or before a treatment-decision was made. Given the fact that request for 
tests may indirectly carry prognostic value, the missing information may possibly bias our finding. Although 
the multiple imputation method was used to estimate the missing values, it could neither provide an unbiased 
estimation nor eliminate potential confounding. Therefore, future studies are required to examine the model 
performance based on laboratory variables with more complete data. Third, because we do not know whether the 
patients who were censored due to loss to follow-up were as likely to have a subsequent event as those individuals 
who remained in the study, informative censoring may occur and bias the results61, 62. Fourth, some important 
factors such as HER2 status and target therapy were not included in the final model due in part to the missing 
Figure 2. Assessment of model performance. The receiver operating characteristics curves were used to assess 
the performance of the final model in the training and testing sets.
Figure 3. Disease free survival of different risk groups stratified by the final model. Kaplan-Meier survival 
estimates were used to characterize patients of different risk groups classified by the final model in the training 
(A) and testing (B) sets.
www.nature.com/scientificreports/
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data. Considering that HER2 is also essential for making treatment decision, and target therapy in HER2 posi-
tive patients could affect patient survival, further study could explore the performance of a model incorporating 
these two variables. Fifth, the patients included in the study were diagnosed between 1988 and 2011. Changes of 
diagnosis criteria and treatment regimens in this relatively long time period might increase the heterogeneity of 
our population. Sixth, we excluded the patients due to the lack of laboratory variable measurement, which might 
confound the results. However, when we compared the basic demographic and clinical characteristics between 
the included and excluded patients, we did not find significant difference in most of these variables (data not 
shown), indicating that the confounding, if there is any, may be minor. Moreover, we excluded some patients 
according to a given clinical characteristics, for example, without surgery. This study design, although made the 
study population more homogeneous, might restrict the generalization of our final model. Finally, this model per-
forms well as a prognostic model to predict DFS of all patients once identified as breast cancer, but there is a lack 
of efficiency on predicting the responses to treatments that were used afterwards. This prediction model can be 
better developed if the follow-up and evaluation of treatments at different time point are included in the analyses.
Variables Coefficients SE
Age 0.03 0.004
Race (Caucasian as reference)
 African American 0.21 0.13
 others 0.15 0.23
Stage (stage I as reference)
 II 0.29 0.17
 III 1.07 0.23
 IV 1.87 0.28
Tumor size (2–9 mm as reference)
 10–29 mm −0.07 0.20
 30–49 mm −0.11 0.15
 50–99 mm 0.06 0.21
 ≥10 cm 0.08 0.21
 Unknown/not found 0.07 0.40
Lymph nodes metastatic rate (0% as reference)
 1–20% −0.11 0.20
 20–49% −0.15 0.26
 50–79% −0.15 0.31
 80–100% 0.38 0.26
 Not determined 0.08 0.17
 Unknown 0.06 0.23
ER status (Negative as reference)
 Positive −0.18 0.20
 Unknown 0.14 1.05
PR status (Negative as reference)
 Positive −0.15 0.18
 Unknown −0.13 1.04
Chemotherapy (without chemotherapy as reference)
 With chemotherapy 0.08 0.42
 Unknown 0.02 0.14
Radiation therapy (without radiation therapy as reference)
 With radiation 0.26 0.35
 Unknown −0.43 0.12
Hormone therapy (without hormone therapy as reference)
 With hormone −0.30 0.27
 Unknown 0.002 0.13
Square of HGB* −0.004 0.001
Nature Logarithm of ALP* 0.35 0.17
Inverse cube of INR* −0.47 0.20
Table 3. Parameter estimates and standard errors in the final model. Abbreviations: ER, estrogen receptor; PR, 
progesterone receptor; HGB, hemoglobin; ALP, alkaline phosphatase; INR, international normalized ratio; SE, 
standard error. *In order to calculate the prognostic index for the testing set, the missing data of HGB, ALP, and 
INR in the testing set were imputed as the mean values from the training set (after normality transformation, 
154.57 for HGB, 4.24 for ALP, and 0.93 for INR, respectively).
www.nature.com/scientificreports/
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In summary, we developed an inexpensive model that was mainly based on readily available objective data for 
a cohort of breast cancer patients identified and treated in a single-institute. If further validated, this model could 
be used to identify breast cancer patients who are at high risk of recurrence and be helpful to motivate individuals 
to pursue benefits from treatments.
Methods
Study population. Based on the electronic medical records from the Cancer Registry at Thomas Jefferson 
University Hospital, we identified histologically confirmed female breast cancer patients who were diagnosed 
and/or treated from October, 1988 to December, 201119. For the analyses in this study, we excluded the patients 
(i) without mastectomy or breast conservation surgery and/or without routine blood tests within 3 months 
after surgery; (ii) with 0/unknown stage and/or cancer histology of carcinoma in situ (including ductal carci-
noma in situ and lobular carcinoma in situ); (iii) without recurrence information or never disease free. Finally, 
a cohort of 1,596 breast cancer patients was selected based on these criteria (Fig. 1). This study was approved 
by the Institutional Review Board (IRB) at the Thomas Jefferson University. Because this study was based on 
data obtained from the review of archived medical charts, patient consent was waived by the IRB of the Office 
of Human Research in Thomas Jefferson University under an approved protocol including the approval for the 
request for waiver of authorization to collect protected health information.
Data collection. Demographic variables including age, race/ethnicity, smoking status, and drinking status 
were collected in this study. Basic clinical variables included tumor size, stage, grade, histology, lymph nodes 
metastatic rate, ER status, PR status, and treatments (hormone therapy, chemotherapy, and radiation therapy). 
Routine blood-based laboratory test data were also obtained from medical charts, which included a total of 33 
variables in four categories: complete blood count (CBC), comprehensive metabolic panel (CMP), coagulation 
panel, and leukocyte differentiation tests (Supplementary Table S1). Following 10 variables were included in the 
CBC panel: white blood cell (WBC), red blood cell (RBC), hemoglobin (HGB), hematocrit (HCT), mean cor-
puscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration 
(MCHC), red cell distribution width (RDW), mean platelet volume (MPV), and platelet count. Routine CMP 
panel recorded 10 variables including blood urine nitrogen (BUN), creatinine, glucose, protein, albumin, alkaline 
phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, and anion 
gap. The coagulation condition of each patient was evaluated by prothrombin time (PT), partial thromboplastin 
time (PTT), and international normalized ratio (INR). The percentages of neutrophils, lymphocytes, monocytes, 
basophils, eosinophils as well as their absolute numbers were all obtained from the results of a test for leukocyte 
differentiation.
Statistical analysis. General analytic strategy. SAS (Version 9.2, SAS institute, Cary, NC) and Stata 
(Version 12.0, Stata Corp., College station, TX) software packages were used for data analyses in this study. The 
clinical endpoint analyzed in this study was DFS. The definition of recurrence was that after surgical removal of 
primary tumor, the regrowth of tumor in the original site or regional lymph nodes, or distant organs. DFS was 
defined as the time from surgery to the first event of either recurrence or death63. Patients who were alive and 
recurrence-free on December 31, 2011 were censored. Patients who were lost to follow-up were censored as well. 
In routine blood-based laboratory tests, variables with greater than 50% missing observations were excluded from 
analyses. For patients with multiple measurements of the same variable, the mean value of these measurements 
were calculated and used in the analyses. To develop a risk prediction model, patients were sorted by surgery date 
and two of every three sorted patients were included in the training set. The remaining patients were included in 
the testing set to internally assess the predictive performance and control overfitting of the model64, 65. All statisti-
cal tests were two-sided, and a P-value of less than 0.05 was considered statistically significant.
Identification of candidate variables. Comparisons of demographic, clinical, and laboratory variables between 
training and testing sets were performed using the chi-square test for categorical variables and Student’s t test for 
continuous variables. The association between each variable and patient DFS was assessed using Kaplan-Meier 
and Cox proportional hazards regression analyses in the training set. Variables that demonstrated a significant 
Groups
No. of patients disease 
free/recurrence
Median DFS time 
(year) HR (95% CI) Cox P Log-rank P
Training set
Low-risk 287/68 NR 1.00 <0.0001
Medium-risk 247/108 10.00 (8.14–11.93) 1.75 (1.30–2.38) 0.0003
High-risk 149/205 4.26 (3.32–4.92) 4.66 (3.54–6.14) <0.0001
Testing set
Low-risk 151/26 NR 1.00 <0.0001
Medium-risk 133/45 10.77 (8.77–12.51) 1.98 (1.22–3.21) 0.006
High-risk 86/91 5.66 (3.72–7.43) 5.33 (3.44–8.27) <0.0001
Table 4. Summary of disease free survival by risk category. Abbreviations and definitions: DFS, disease free 
survival; HR, hazard ratio; CI, confidence interval; NR, not reached.
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association with DFS were included in the next stepwise selection and model construction. Laboratory variables 
had to be significant in all of the categorical, continuous, and log-rank analyses. Bootstrap resampling method 
is used to internally validate the analyses of these results. A total of 1,000 bootstrap samples were generated for 
each analysis. Each time a bootstrap was drawn from the original dataset and the P-value for the analysis was 
calculated. The number of times with a P-value less than 0.05 was counted.
Stepwise selection and model construction. In order to minimize the confounding effects resulting from poten-
tial high correlations between laboratory variables and demographic and clinical variables, we forced significant 
demographic and clinical variables from the univariate analysis into the model. For the laboratory variables, we 
conducted stepwise selection using multivariate Cox proportional hazards model with significant laboratory var-
iables identified in the univariate analysis. All continuous variables were kept continuous in the multivariate Cox 
regression and model construction process to avoid loss of power and residual confounding66. Multiple imputa-
tion method was used to handle the missing data in the training set67. The 10 imputation datasets from the train-
ing set were generated by Stata’s MI package, basing on the multivariate normal imputation68. And the missing 
data in the testing set were imputed as the mean values from the training set. Before imputation, box-cox method 
was used to transform variables with skewed distribution toward normality. In each imputed dataset, a forward 
stepwise selection was conducted using Akaike’s information criterion (AIC) which balances the data fitting and 
complexity of the model and reduced risk of overfitting69. The model with the smallest AIC was selected as the 
best model for each imputed dataset. The significant demographic and clinical variables were forced into the final 
model which was derived from each of the 10 imputed dataset as a composite. A laboratory variable which was 
selected in at least 6 imputed datasets was included in the final model. The parameter estimate (weight/coeffi-
cients) of each variable was calculated based on the pooled imputed datasets. A prognostic index was derived by 
calculating the sum of each variable multiplied by its corresponding weight in the final model.
Model validation. Two methods were used for model validation and applied in both training and testing sets. 
Model’s capability to predict recurrence was assessed by constructing the ROC curves and calculating the AUCs70.
In the second validation method, patients were classified into three risk groups based on the prognostic index 
calculated by the model. The cutoff value was determined by tertile distribution of the prognostic index. HRs with 
95% CI in different risk groups were assessed by Cox proportional hazards model. Survival curves were plotted 
using Kaplan-Meier method and compared using the log-rank test.
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